低分子肝素治疗小儿肾病综合征的临床疗效分析

Analysis on the Clinical Effect of Low Molecular Weight Heparin in the Treatment of Children with Nephrotic Syndrome

目的探讨低分子肝素治疗小儿肾病综合征的临床疗效。方法以近年来于我院治疗的114例原发性肾病综合征患儿为研究对象,将其随机分为常规组和观察组各57例,常规组使用免疫抑制剂和激素类药物进行常规治疗,观察组于常规组治疗的基础上增加使用低分子肝素钠进行治疗。对两组患儿的临床疗效进行观察对比。结果治疗后观察组患者有效率达93.0%,明显优于常规组71.9%,差异有统计学意义(P<0.05)。治疗期间两组患儿均未发生出血、肝肾功能损伤和严重不良反应情况。治疗后观察组患儿24 h尿蛋白、血清白蛋白、总胆固醇和D-二聚体均显著优于常规组,均P<0.05;治疗后两组患儿凝血酶原时间、部分凝血活酶时间和血小板与治疗前无明显变化(P>0.05)。结论于常规治疗基础上增加使用低分子肝素对小儿肾病综合征进行治疗安全方便,能够显著提高治疗效果,改善患儿的临床症状,无出血和肝肾功能损伤等并发症或不良反应发生。

Objective To investigate the clinical effect of low molecular weight heparin in the treatment of children with nephrotic syndrome. Methods 114 children with primary nephrotic syndrome were randomly divided into two groups, with 57 cases in each group. The routine group received conventional therapy with immune inhibitors and hormone drugs, while the observation group received the treatment of low molecular weight heparin sodium on the basis of conventional therapy. The clinical effects of two groups were observed and compared. Results The effective rate of observation group was 93.0%, significantly higher than 71.9% of routine group （P 〈0.05）. No bleeding, liver and kidney dysfunction or other serious adverse reaction was found in both groups during therapy. The 24-hour urinary protein, serum albumin, total cholesterol, and D-dimer of observation group were better than those of routine group, and the differences were statistically significant （P 〈0.05）. After therapy, there were no significant changes of prothrombin time, partial thromboplastin time, and platelet in both groups （P 〉0.05）. Conclusions The use of low molecular weight heparin on the basis of conventional therapy for children with nephrotic syndrome is safe and convenient. It can significantly improve curative effect, and improve children＇s clinical symptoms, at the same time, it will not cause the occurrence of bleeding, liver and kidney dysfunction or other serious adverse reaction.